Kyverna Therapeutics, Inc. - 8-K Filing
Kyverna Therapeutics held its 2026 Annual Meeting of Stockholders on May 27, 2026. Shareholders elected Ian Clark and Christi Shaw as Class II directors with over 73% quorum participation and ratified BDO USA, P.C. as the independent auditor for fiscal year ending December 31, 2026. (Items: 5.07 Submission of Matters to a Vote of Security Holders, 9.01 Financial Statements and Exhibits)
Tickers: $KYTX